In short
This article discusses the clinical trials of STC-1010, an innovative immunotherapy drug being tested for patients with advanced or metastatic colorectal cancer. The BreAK CRC trial aims to evaluate the safety, efficacy, and optimal dosing of STC-1010 when combined with standard-of-care treatments. This study offers hope for patients with limited treatment options and may potentially improve outcomes for those battling this challenging disease.
At a glance
- Study Name
- BreAK CRC trial (BreAK for Brenus Anti-cancer)
- Drug Tested
- STC-1010 (immunotherapy)
- Target Condition
- Unresectable locally advanced or metastatic colorectal cancer
- Study Design
- Open-label, multicenter, Phase I/IIA trial
- Primary Objectives
- Phase I: Safety profile and optimal dose determination; Phase IIA: Clinical efficacy assessment
- Key Eligibility
- Adults 18-75 years, specific tumor characteristics (MSS or MSI-H), adequate organ function
- Treatment Regimen
- STC-1010 + standard of care (mFOLFOX6 + bevacizumab)
- Primary Endpoint
- Phase IIA: Progression-free survival rate at 12 months
What is STC-1010?
STC-1010 is a new immunotherapy drug being studied for the treatment of advanced or metastatic colorectal cancer. It is currently undergoing clinical trials to assess its safety and effectiveness. STC-1010 is also known as "Stimulated Tumor Cells-1010," which gives us a clue about how it works.
How Does STC-1010 Work?
STC-1010 is a type of cell therapy, which means it uses specially prepared cells to fight cancer. It contains six different components, each derived from different colorectal cancer cell lines: HCT116-A and HCT116-B HT-29-A and HT-29-B LOVO-A and LOVO-B These cells are likely modified to stimulate the patient's immune system to recognize and attack cancer cells more effectively.
STC-1010 is administered as a solution for injection, typically given intradermally (into the skin). This method of administration helps to activate the immune system locally.
Who Might Benefit from STC-1010?
STC-1010 is being studied in patients with: Unresectable locally advanced colorectal cancer (cancer that has spread locally but cannot be surgically removed) Metastatic colorectal cancer (cancer that has spread to other parts of the body) The trial is focusing on two main groups of patients: Patients with MSS (microsatellite stable) tumors who haven't received prior treatment Patients with MSI-H (microsatellite instability-high) tumors, including those with Lynch syndrome, who have progressed after at least 4 months of prior immunotherapy
Clinical Trial Details
The clinical trial for STC-1010 is called the "BreAK CRC trial" and is divided into two phases:
Phase I: Dose Escalation
This phase aims to: Determine the safety of STC-1010 when combined with standard chemotherapy Find the right dose for further testing Patients in this phase will receive STC-1010 along with a chemotherapy regimen called mFOLFOX6 and a drug called bevacizumab.
Phase IIA: Cohort Expansion
This phase will further test STC-1010 in two groups: Arm 2A-1: Patients with MSS tumors receiving first-line treatment Arm 2A-2: Patients with MSI-H tumors who have progressed after prior immunotherapy The main goal is to see how well STC-1010 works in stopping cancer growth or shrinking tumors.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key points include:
Inclusion Criteria:
- Age 18-75 years
- Confirmed diagnosis of unresectable locally advanced or metastatic colorectal cancer
- Adequate organ function (blood counts, liver, and kidney function)
- Measurable disease according to specific criteria (RECIST 1.1)
Exclusion Criteria:
- Rapidly progressing disease with life-threatening complications
- Active autoimmune diseases
- Recent major surgery or radiation therapy
- Active infections or other severe medical conditions
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to consider:
Potential Benefits:
- Access to a new treatment that may be more effective than standard therapies
- Close monitoring and care from a specialized medical team
- Contribution to the advancement of cancer research
Potential Risks:
- Unknown side effects or unexpected reactions to the treatment
- The treatment may not be effective for everyone
- Time commitment for frequent hospital visits and tests
It's important to discuss these potential benefits and risks thoroughly with your healthcare provider before considering participation in the clinical trial.